News
As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...
AstraZeneca Readies for Tagrisso Competition in First-Line Advanced Lung Cancer as Q2 Revenues Surge
The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.
Neurologists from multiple clinics presented data at AAIC on Leqembi's use, shedding light on its safety and efficacy outside ...
The firm will retain rights to its preclinical assets including two T-cell receptor T-cell therapies and its allogenic program.
The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.
The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.
Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...
The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...
NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended regulators approve Servier's IDH1/2 inhibitor Voranigo (vorasidenib) as a treatment for ...
The Medicines and Healthcare Products Regulatory Agency said it will closely track adverse events associated with the treatment.
Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results